Compare BTU & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | SUPN |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | 6600 | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2001 | 2010 |
| Metric | BTU | SUPN |
|---|---|---|
| Price | $23.20 | $45.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $32.83 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 3.7M | 571.0K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,861,500,000.00 | $392,755,000.00 |
| Revenue This Year | $17.96 | $22.70 |
| Revenue Next Year | $5.47 | $19.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.67 | $31.16 |
| 52 Week High | $41.14 | $59.68 |
| Indicator | BTU | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 36.16 | 47.46 |
| Support Level | N/A | $43.43 |
| Resistance Level | $31.39 | $46.79 |
| Average True Range (ATR) | 1.31 | 1.34 |
| MACD | -0.45 | 0.20 |
| Stochastic Oscillator | 1.79 | 71.19 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.